“Real-World Outcomes, Treatment Patterns and T790M Testing Rates in Non-Small Cell Lung Cancer Patients Treated With First-Line First- or Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors from the Slovenian Cohort of the REFLECT: Outcomes and Treatments of EGFR-Mutated NSCLC Patients from Slovenia”. 2022. Radiology and Oncology 56 (3): 371-79. https://www.radioloncol.com/index.php/ro/article/view/3840.